rs45501594
Variant summary
Our verdict is Benign. Variant got -13 ACMG points: 0P and 13B. BP4_StrongBP6BS1BS2
The NM_001378454.1(ALMS1):āc.10628C>Gā(p.Thr3543Ser) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0109 in 1,613,648 control chromosomes in the GnomAD database, including 114 homozygotes. In-silico tool predicts a benign outcome for this variant. 10/16 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_001378454.1 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -13 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.00669 AC: 1017AN: 152074Hom.: 4 Cov.: 32
GnomAD3 exomes AF: 0.00664 AC: 1642AN: 247312Hom.: 14 AF XY: 0.00680 AC XY: 913AN XY: 134240
GnomAD4 exome AF: 0.0114 AC: 16640AN: 1461456Hom.: 111 Cov.: 32 AF XY: 0.0110 AC XY: 8026AN XY: 727014
GnomAD4 genome AF: 0.00667 AC: 1015AN: 152192Hom.: 3 Cov.: 32 AF XY: 0.00593 AC XY: 441AN XY: 74414
ClinVar
Submissions by phenotype
not provided Benign:5
- -
- -
This variant is associated with the following publications: (PMID: 26239645, 25846608) -
ALMS1: BP4, BS1, BS2 -
- -
Alstrom syndrome Uncertain:1Benign:3
- -
- -
- -
Potent mutations in ALMS1 are associated with a rare condition called Alstrom syndrome. It can cause excessive eating, insulin resistance. However, no evidence is found to ascertain the role of rs45501594 in Alstrom syndrome yet. -
not specified Benign:3
p.Thr3542Ser in exon 16 of ALMS1: This variant is not expected to have clinical significance because it has been identified in 1.03% (1297/125086) of European c hromosomes including 12 homozygotes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org/; dbSNP rs45501594). -
Variant summary: The ALMS1 c.10625C>G (p.Thr3542Ser, alternative name c.10631C>G) variant involves the alteration of a non-conserved nucleotide. 4/5 in silico tools predict a benign outcome for this variant. This variant was found in 824/119494 control chromosomes (5 homozygotes), predominantly observed in the European (Non-Finnish) subpopulation at a frequency of 0.0099462 (658/66156). This frequency is about 4 to 7 times the estimated maximal expected allele frequency of a pathogenic ALMS1 variant (0.0022361) for CYMO or Alstrom Syndrom, respectively. The allele frequency in the European (Non-Finnish) subpopulation suggests that this variant is likely a benign polymorphism found primarily in the populations of European (Non-Finnish) origin. The variant has been reported in patients with clinical features of Alstrom Syndrome, but without evidence of causality (ie co-segregation or functional studies). In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as benign. Taken together, this variant is classified as benign. -
- -
Monogenic diabetes Benign:1
ACMG criteria: BP4 (six predictors plus Revel score: 0.024; not using PP3's three predictors), BA1 (1% in gnomAD European population), BS2 (15 homozygotes in gnomAD), BP1 (missense variant when mostly truncating mutations)= benign -
Cardiovascular phenotype Benign:1
This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at